证券代码：301230 证券简称：泓博医药 公告编号：2023-033 上海泓博智源医药股份有限公司 第三届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第三届董事会第十一次会议 通知于2023年8月16日以邮件的形式送达全体董事。会议于2023年8月25日上午10:30 以现场结合通讯会议的方式召开。会议应出席董事 7 名，实际出席 7 名。本次会议由董 事长 Ping Chen 博士主持召开，公司监事、高级管理人员列席了会议。会议召开及表决 程序符合《中华人民共和国公司法》及《上海泓博智源医药股份有限公司章程》(以下 简称"《公司章程》")的有关规定。 二、董事会会议审议情况 公司募集资金的使用与管理符合《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》和公司《募集资金管理制度》的相关规定，及时、真实、准确、完 整地披露了募集资金的存放与使用情况。报告期内募 ...

证券代码：301230 证券简称：泓博医药 公告编号：2023-035 上海泓博智源医药股份有限公司 1、实际募集资金金额、资金到位时间 经中国证券监督管理委员会 2022 年 7 月 8 日证监许可[2022] 1443 号文同意注册， 本公司向社会公开发行人民币普通股 19,250,000.00 股，每股面值人民币 1.00 元，每股 发行价格为人民币 40.00 元，募集资金总额为人民币 770,000,000.00 元，由主承销商中 信证券扣除保荐承销费 60,000,000.00 元后，将剩余募集资金 710,000,000.00 元汇入公司 开立的募集资金专用账户。扣除公司本期募集资金到账后为发行股份所支付的其他发行 费用 13,921,509.29 元，扣除公司应转出的先期以自有资金垫付其他发行费用 9,190,622.34 元，扣除后续仍需支付的发行费用 1,039,429.66 元，实际募集资金净额为 685,848,438.71 元，其中计入股本 19,250,000.00 元，资本溢价 666,598,438.71 元计入资 本公积，新增股本占新增注册资本的 100%。上述资金于 202 ...

证券代码：301230 证券简称：泓博医药 公告编号：2023-034 上海泓博智源医药股份有限公司 第三届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第三届监事会第七次会议通 知于 2023 年 8 月 16 日以邮件形式送达全体监事。会议于 2023 年 8 月 25 日上午 11:00 以现场结合通讯会议的方式召开。本次会议由监事会主席刘国东先生主持召开，应出 席监事 5 名，实际出席 5 名。会议召开及表决程序符合《中华人民共和国公司法》及 《上海泓博智源医药股份有限公司章程》的有关规定。 二、监事会会议审议情况 经出席会议的全体监事认真审议，通过了如下议案： 1、审议通过《关于<2023 年半年度报告及其摘要>的议案》 经审核公司编制的《2023 年半年度报告》及《2023 年半年度报告摘要》，监事会 认为《2023 年半年度报告》和《2023 年半年度报告摘要》的内容与格式符合中国证监 会和深圳证券交易所的各项规定，其审议、表决程序符合法律法规、规 ...

上海泓博智源医药股份有限公司独立董事 关于公司第三届董事会第十一次会议相关事项的独立意见 经核查，我们认为：上述报告客观、真实地反映了公司 2023 年半年度募集资金 存放与使用的实际情况。公司募集资金的存放和使用符合《深圳证券交易所创业板 股票上市规则》、《上市公司自律监管指引第 2 号——创业板上市公司规范运作》、 《公司章程》和《募集资金管理制度》等有关规定的要求，公司对募集资金的管理 遵循专户存放、严格管理、规范使用、及时披露的原则，不存在变相改变募集资金 投向、损害股东利益及违反相关规定的情形。 因此，我们一致同意《关于<2023 年半年度募集资金存放和使用情况专项报告> 的议案》。 二、关于控股股东及其他关联方占用公司资金、公司对外担保情况的独立意见 根据中国证监会发布的《上市公司监管指引第 8 号——上市公司资金往来、对 外担保的监管要求》等相关文件规定和《公司章程》等相关法律、法规的有关规定， 我们认为： 1、报告期内，公司不存在控股股东及其他关联方违规占用公司资金的情况，也 不存在以前年度发生但延续到报告期的控股股东及其他关联方违规占用公司资金的 情况； 2、报告期内，公司为子公司提供 2, ...

编号：2023-004 | 投资者关系活动 | □ 特定对象调研 □ 分析师会议 □√ 业绩说明会 | □ 媒体采访 | | | --- | --- | --- | --- | | 类别 | □ 新闻发布会 □ 路演活动 | □ 现场参观 | □其他（线上会议） | | 参与单位名称及 | 线上参与公司 2022 年度业绩说明会的全体投资者 | | | | 人员姓名 | | | | | 时间 | 2023 年 5 月 5 日 (周五) 下午 15:00~16:00 | | | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 上市公司接待人 | 1、董事长、总经理 PING CHEN | | | | 员姓名 | 2、董事、副总经理、董事会秘书 蒋胜力 | | | | | 李世成 3、财务总监 | | | | | 程立 4、独立董事 | | | | 投资者关系活动 | 投资者提出的问题及公司回复情况 | | | | 主要内容介绍 | 公司就投资者在本次说明会中提出的问题进行了回复： | | | | | 1、请问公司拟向特定对象进行简易程序融资的资金规模是多少？该 ...

证券代码：301230 证券简称：泓博医药 公告编号：2023-019 上海泓博智源医药股份有限公司 关于举行2022年度网上业绩说明会的公告 上海泓博智源医药股份有限公司 为充分尊重投资者，提升交流的针对性，现就公司 2022 年度网上业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 4 日(星 期四)15:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面进行 提问。公司将在本次业绩说明会上对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海泓博智源医药股份有限公司(以下简称"公司")于 2023 年 4 月 22 日披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便于广大投资者进一步了解公司生产经营 等情况，公司定于 2023 年 5 月 5 日(星期五)15:00-16:00 在全景网举行 2022 年度网上业 绩说明会，本次年度业绩说明会将采用网络远程 ...

Financial Performance - The company's revenue for Q1 2023 was ¥121,392,447.24, representing a 16.37% increase compared to ¥104,314,490.66 in the same period last year[7] - Net profit attributable to shareholders was ¥15,275,796.35, a 47.03% increase from ¥10,389,651.14 year-on-year[7] - The basic earnings per share increased to ¥0.20, up 11.11% from ¥0.18 in the previous year[7] - The total profit for the period was ¥17,237,207.56, a 47.31% increase compared to ¥11,701,557.15 in the previous year[11] - Net profit for Q1 2023 reached CNY 15,275,796.35, representing a 46.5% increase from CNY 10,389,651.14 in Q1 2022[23] - The company reported a total comprehensive income of CNY 15,358,257.21 for Q1 2023, compared to CNY 10,440,458.21 in the previous year[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,304,372,027.11, a slight increase of 0.24% from ¥1,301,260,787.30 at the end of the previous year[7] - Total current assets amount to ¥937,645,629.92, slightly up from ¥936,534,975.25 at the beginning of the year[19] - Total liabilities as of Q1 2023 were CNY 173,306,295.87, down from CNY 188,376,403.68 in the previous year[23] - Total current liabilities decreased to ¥91,455,047.87 from ¥100,874,095.92, a reduction of about 9.4%[19] - Non-current liabilities include lease liabilities of ¥78,264,069.34, down from ¥80,426,253.75[19] Cash Flow - The net cash flow from operating activities decreased by 50.88% to ¥13,556,647.25, down from ¥27,600,828.05 in the same period last year[12] - Cash flow from operating activities for Q1 2023 was CNY 13,556,647.25, a decrease of 50.9% from CNY 27,600,828.05 in Q1 2022[25] - The cash flow from investment activities showed a significant outflow of ¥425,843,102.78, indicating substantial investment in construction projects[12] - The net cash flow from investment activities was -425,843,102.78 CNY, indicating a significant outflow compared to the previous period[26] - Total cash inflow from financing activities was 2,243,221.74 CNY, while cash outflow was 4,653,403.39 CNY, resulting in a net cash flow of -4,653,403.39 CNY[26] - The net increase in cash and cash equivalents for the quarter was -418,568,830.61 CNY, a notable decrease from the previous quarter[26] - The ending balance of cash and cash equivalents was 335,073,505.57 CNY, down from 753,642,336.18 CNY at the beginning of the period[26] - Cash outflow for the acquisition of fixed assets and intangible assets totaled 70,662,185.02 CNY[26] - The company reported a total cash outflow from investment activities of 580,262,185.02 CNY[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,013[14] - The largest shareholder, Hongbo Zhiyuan (Hong Kong) Medical Technology Co., Ltd., holds 27.64% of shares, totaling 21,250,000 shares[14] - The top ten shareholders collectively hold significant stakes, with the top three accounting for over 39.49% of total shares[14] Expenses - Sales expenses increased by 68.35% to ¥2,563,164.87, reflecting increased investment in market development[11] - Total operating costs for Q1 2023 were CNY 104,504,260.72, up 13.1% from CNY 92,457,818.09 in the same period last year[22] - Research and development expenses increased to CNY 10,163,571.92 in Q1 2023, up 27.5% from CNY 7,974,960.23 in Q1 2022[22] Other Information - The company received government subsidies amounting to ¥413,168.87, related to its normal business operations[9] - The company recorded a significant increase in fair value gains of CNY 901,397.80 in Q1 2023, compared to a loss of CNY 395,647.75 in Q1 2022[23] - The company did not conduct an audit for the first quarter report[27] - The company experienced a foreign exchange loss of -1,628,971.69 CNY affecting cash and cash equivalents[26]

Financial Performance - The company reported a total revenue of RMB 500 million for the year 2022, representing a year-on-year increase of 25%[16] - The net profit attributable to shareholders was RMB 100 million, an increase of 15% compared to the previous year[16] - The company's operating revenue for 2022 was ¥478,883,784.02, representing a 6.84% increase compared to ¥448,213,754.22 in 2021[21] - The net profit attributable to shareholders for 2022 was ¥67,175,882.45, a decrease of 8.70% from ¥73,576,617.25 in 2021[21] - The net profit after deducting non-recurring gains and losses was ¥62,640,367.44, down 10.81% from ¥70,228,583.34 in 2021[21] - The total assets at the end of 2022 reached ¥1,301,260,787.30, a significant increase of 133.28% from ¥557,806,841.51 at the end of 2021[21] - The net assets attributable to shareholders increased by 219.39% to ¥1,112,884,383.62 at the end of 2022, compared to ¥348,441,182.99 at the end of 2021[21] - The basic earnings per share for 2022 was ¥1.10, down 14.06% from ¥1.28 in 2021[21] - The cash flow from operating activities for 2022 was ¥99,294,136.99, a decrease of 5.55% from ¥105,124,189.11 in 2021[21] Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[16] - The company anticipates a revenue growth of 30% for 2023, driven by new product launches and market expansion[16] - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, with a total payout based on 76,873,333 shares[6] - The company is actively expanding its domestic business to promote balanced development between domestic and international operations[132] - The company plans to strengthen its marketing system to provide professional end-to-end services, focusing on customer orientation[132] - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 200 million RMB allocated for this purpose[168] Research and Development - New product development includes a pipeline of 5 innovative drugs expected to enter clinical trials in 2023[16] - The company has invested RMB 50 million in AI-driven drug design technologies to enhance R&D efficiency[16] - The R&D expenditure for 2022 was RMB 80 million, accounting for 16% of total revenue, reflecting a commitment to innovation[16] - Research and development (R&D) expenses for 2022 amounted to CNY 3,265.26 million, with a CAGR of 66.14% over the past three years[62] - R&D expenses accounted for 6.82% of the total operating revenue in 2022, up from 3.83% in 2021[62] - The number of R&D personnel increased to 669 in 2022, making up 68.06% of the total workforce of 983 employees[64] - The company has established multiple new technology platforms, including CADD/AIDD drug design, continuous flow chemistry, solid-state chemistry, and asymmetric catalysis, to enhance its R&D capabilities[103] - The company aims to leverage its R&D capabilities to support the commercialization of innovative drugs, ensuring efficient transition from laboratory research to clinical applications[59] Product Development and Innovation - The company’s new drug development model involves deep integration with clients, utilizing a multidisciplinary approach to enhance the efficiency of drug discovery[55] - The company has delivered a total of 33 candidate drug molecules, with 27 of them being FIC projects, accounting for 81.82%[86] - The company has developed key technologies in drug discovery and process development, including CADD/AIDD and enzyme catalysis, enhancing its R&D capabilities[68] - The CADD/AIDD technology platform has supported 44 new drug projects, with 2 entering clinical phase I and 2 in the clinical application stage[77] - The company has filed multiple patents related to drug intermediates and synthesis methods, showcasing its innovation capabilities[73] Operational Efficiency and Management - The company aims to improve operational efficiency by 10% through process optimization initiatives[168] - The company has established a comprehensive training and development system to enhance employee skills and overall organizational efficiency[193] - The company has a governance structure in place, including a general meeting of shareholders, a board of directors, and a supervisory board, to ensure effective internal control[199] - The company has a clear organizational structure with defined roles and responsibilities, facilitating independent operational activities[152] - The company has a dedicated financial department with an independent accounting system, ensuring financial decisions are made autonomously[152] Corporate Governance and Compliance - The company emphasizes information disclosure, adhering to laws and regulations, and utilizes multiple media outlets for transparency[150] - The company has established a strong talent reserve, with a management team and R&D team comprising experts with extensive international experience in drug development[66] - The company has taken steps to enhance its governance structure, ensuring compliance with relevant laws and regulations, which supports long-term sustainable development[147] - The company has a supervisory board consisting of 5 members, including 2 employee representatives, ensuring compliance with legal requirements[149] Financial Management and Cash Flow - Operating cash inflow increased by 22.48% year-on-year to ¥511,293,713.11, primarily due to VAT refunds received during the reporting period[104] - Operating cash outflow rose by 31.92% year-on-year to ¥411,999,576.12, mainly attributed to the expansion of production and operational scale[104] - The company reported a significant increase in government subsidies, contributing ¥4,772,986.00 to other income, which accounted for 6.55% of total profit[106] - The company’s cash dividend policy requires that at least 30% of the average distributable profit over the last three years be distributed in cash if certain conditions are met[195] Employee and Management Compensation - The total remuneration paid to directors, supervisors, and senior management in 2022 amounted to 7.21 million yuan, including 600,000 yuan for independent directors' allowances[180] - The company has a diverse board with independent directors and various management roles, ensuring a range of expertise[181] - The remuneration decision-making process involves the compensation and assessment committee, which establishes salary plans based on company performance and industry benchmarks[180] - The company has established a salary system based on fairness, competitiveness, and performance incentives[192] Future Outlook - Future guidance suggests a positive outlook for revenue growth, driven by new product launches and market expansion strategies[158] - The company plans to increase R&D investment in 2023, aiming to establish the PR-GPT platform to enhance drug design efficiency[77] - The company aims to enhance its market position by accelerating capacity layout and improving core competitiveness through technology platform development[132]